Health-related quality of life of daily-life-affected benign essential blepharospasm: Multi-center observational study
Issued Date
2023-03-01
Resource Type
eISSN
19326203
Scopus ID
2-s2.0-85150283216
Pubmed ID
36920965
Journal Title
PLoS ONE
Volume
18
Issue
3 March
Rights Holder(s)
SCOPUS
Bibliographic Citation
PLoS ONE Vol.18 No.3 March (2023)
Suggested Citation
Hirunwiwatkul P., Supawatjariyakul W., Jariyakosol S., Apinyawasisuk S., Sriratanaban J., Chongpison Y., Jagota P., Aui-Aree N., Witthayaweerasak J., Setthawatcharawanich S., Kitthaweesin K., Chirapapaisan N., Chaimongkoltrakul P., Laowanapiban P., Hansapinyo L., Panpitpat S., Kurathong S., Nimworaphan J., Thitiwichienlert S., Vanikieti K., Samipak N., Srimanan W., Mekhasingharak N., Chaitanuwong P. Health-related quality of life of daily-life-affected benign essential blepharospasm: Multi-center observational study. PLoS ONE Vol.18 No.3 March (2023). doi:10.1371/journal.pone.0283111 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82143
Title
Health-related quality of life of daily-life-affected benign essential blepharospasm: Multi-center observational study
Author(s)
Hirunwiwatkul P.
Supawatjariyakul W.
Jariyakosol S.
Apinyawasisuk S.
Sriratanaban J.
Chongpison Y.
Jagota P.
Aui-Aree N.
Witthayaweerasak J.
Setthawatcharawanich S.
Kitthaweesin K.
Chirapapaisan N.
Chaimongkoltrakul P.
Laowanapiban P.
Hansapinyo L.
Panpitpat S.
Kurathong S.
Nimworaphan J.
Thitiwichienlert S.
Vanikieti K.
Samipak N.
Srimanan W.
Mekhasingharak N.
Chaitanuwong P.
Supawatjariyakul W.
Jariyakosol S.
Apinyawasisuk S.
Sriratanaban J.
Chongpison Y.
Jagota P.
Aui-Aree N.
Witthayaweerasak J.
Setthawatcharawanich S.
Kitthaweesin K.
Chirapapaisan N.
Chaimongkoltrakul P.
Laowanapiban P.
Hansapinyo L.
Panpitpat S.
Kurathong S.
Nimworaphan J.
Thitiwichienlert S.
Vanikieti K.
Samipak N.
Srimanan W.
Mekhasingharak N.
Chaitanuwong P.
Author's Affiliation
Siriraj Hospital
Faculty of Medicine, Chiang Mai University
Udon Thani Center Hospital
Chulalongkorn University
Faculty of Medicine, Khon Kaen University
Faculty of Medicine, Prince of Songkia University
Naresuan University
King Chulalongkorn Memorial Hospital
Vajira Hospital
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Faculty of Medicine, Thammasat University
Phramongkutklao College of Medicine
Rajavithi Hospital
Faculty of Medicine, Chulalongkorn University
Mettapracharak (Wat Rai Khing) Hospital
Faculty of Medicine, Chiang Mai University
Udon Thani Center Hospital
Chulalongkorn University
Faculty of Medicine, Khon Kaen University
Faculty of Medicine, Prince of Songkia University
Naresuan University
King Chulalongkorn Memorial Hospital
Vajira Hospital
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Faculty of Medicine, Thammasat University
Phramongkutklao College of Medicine
Rajavithi Hospital
Faculty of Medicine, Chulalongkorn University
Mettapracharak (Wat Rai Khing) Hospital
Other Contributor(s)
Abstract
Purpose To compare Thais’ health-related quality of life (HRQOL) and severity grading, efficacy and safety in daily-life-affected benign essential blepharospasm (BEB) patients at baseline and after Botulinum toxin type A (BTX-A) treatment. Design Prospective-observational study. Participants BEB patients with Jankovic rating scale (JRS) at least 3 in both severity and frequency graded from 14 institutes nationwide were included from August 2020 to June 2021. Methods Demographic data, HRQOL evaluated by the Thai version of EQ-5D-5L and NEI-VFQ-25 questionnaires, and severity grading score evaluated by Jankovic rating scale (JRS) at baseline, 1, and 3 months after the treatment were collected. The impact of the BTX-A injections and their complications were recorded. Results 184 daily-life-affected BEB patients were enrolled; 159 patients (86.4%) had complete data with a mean age of 61.40±10.09 years. About 88.05% were female, and 10.1% were newly diagnosed. Most of the patients had bilateral involvement (96.9%) and 12.6% had history of BEB-related accident. After BTX-A treatment, HRQOL improved significantly in 4 dimensions of EQ-5D-5L, except self-care. The EQ_VAS (mean±SD) was 64.54±19.27, 75.13 ±15.37, 73.8±15.85 (p<0.001) and EQ-5D-5L utility score was 0.748±0.23, 0.824±0.19 and 0.807±0.19 at baseline, 1, 3 months after treatment, respectively. From NEI-VFQ-25, HRQOL also improved in all dimensions, except eye pain. The JRS improved in all patients. Self-reported minor adverse events were 22.6%, which mostly resolved within the first month. Conclusion Daily-life-affected BEB impacted HRQOL in most dimensions from both generic and visual-specific questionnaires. BTX-A treatment not only decreased disease severity, but also improved quality of life.